POINT BIOPHARMA GLOBAL INC. Financing Receivable, after Allowance for Credit Loss, Noncurrent
POINT BIOPHARMA GLOBAL INC. had Financing Receivable, after Allowance for Credit Loss, Noncurrent of $5.12 million as of 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments and Receivables, Net
us-gaap:NotesAndLoansReceivableNetNoncurrent · last filed 2023-11-13
- 2023-09-30: Financing Receivable, after Allowance for Credit Loss, Noncurrent $5.12M.
- 2023-06-30: Financing Receivable, after Allowance for Credit Loss, Noncurrent $5.03M.
- 2022-12-31: Financing Receivable, after Allowance for Credit Loss, Noncurrent $0.00.
| Period end | Financing Receivable, after Allowance for Credit Loss, Noncurrent |
|---|---|
| 2023-09-30 | $5.12M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $5.03M 10-Q · filed 2023-08-14 |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-13 |